帕金森病治疗的新进展

doi:10.3969/j.issn.1006-6233.2017.09.051

摘要
图/表
参考文献(29)
相关文章 (1)

[1] Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for parkinson's disease[J].Movement disorders : official journal of the Movement Disorder Society,2015,30:1591~1601.
[2] Chondrogiorgi M, Tatsioni A, Reichmann H, et al. Dopamine agonist monotherapy in parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials[J].European journal of neurology2014,21:433~440.
[3] Hauser RA, Schapira AH, Barone P, et al. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced parkinson's disease[J].European journal of neurology,2014,21:736~743.
[4] Zhang Z, Wang J, Zhang X, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study[J].Parkinsonism &|related disorders,2013,19:1022~1026.
[5] Makumi CW, Asgharian A, Ellis J, et al. Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease[J]. The International journal of neuroscience,2016,126:30~38.
[6] Giladi N, Nicholas AP, Asgharnejad M, et al. Efficacy of rotigotine at different stages of parkinson's disease symptom severity and disability: a post Hoc analysis according to baseline hoehn and yahr stage[J].Journal of Parkinson's disease,2015,6:741~749.
[7] Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors[J].Synapse (New York, N.Y.),2015,69:183~189.
[8] Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety[J].Neurology,2016,86:S13~24.
[9] Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease[J].Movement disorders : official journal of the Movement Disorder Society,2013,28:1064~1071.
[10] Fabbri M, Rosa MM, Ferreira JJ. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease[J]. Neurodegenerative disease management,2016,6:349~362.
[11] Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with parkinson disease and motor fluctuations: a randomized clinical trial[J].JAMA neurology,2016.
[12] Ferreira JJ, Katzenschlager R, Bloem BR, et al.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease[J].European journal of neurology,2013,20:5~15.
[13] Stocchi F, Fossati C, Torti M. Rasagiline for the treatment of Parkinson's disease: an update[J].Expert opinion on pharmacotherapy,2015,16:2231~2241.
[14] Cattaneo C, Sardina M, Bonizzoni E. Safinamide as add-on therapy to levodopa in mid- to late-stage parkinson's disease fluctuating patients: post hoc analyses of studies 016 and SETTLE[J].Journal of Parkinson's Disease,2016,6:165~173.
[15] LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease[J]. Movement disorders : official journal of the Movement Disorder Society,2016,31:1356~13565.
[16] Lopiano L, Modugno N, Marano P, Sensi M, et al. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study[J].Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,2016,37:1785~1792.
[17] Drapier S, Eusebio A, Degos B, et al. Quality of life in parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study[J].Journal of neurology2016,263:1111~1119.
[18] Winkelman JW, Armstrong MJ, Allen RP, et al.Practice guideline summary: treatment of restless legs syndrome in adults: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology[J].Neurology,2016,87:2585~2593.
[19] Schettino C, Dato C, Capaldo G, et al. Rasagiline for sleep disorders in patients with Parkinson's disease: a prospective observational study[J].Neuropsychiatric disease and treatment,2016,12:2497~2502.
[20] Wang Y, Yang YC, Lan DM, et al.An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease[J].Sleep &|breathing = Schlaf &|Atmung,2015.
[21] Ughratdar I, Samuel M, Ashkan K. Technological Advances in deep brain stimulation[J].Journal of Parkinson's Disease,2015,5:483~496.
[22] Bari AA, Fasano A, Munhoz RP, et al. Improving outcomes of subthalamic nucleus deep brain stimulation in Parkinson's disease[J].Expert review of neurotherapeutics,2015,15:1151~1160.
[23] Little S, Bestmann S. Computational neurostimulation for parkinson's disease[J].Progress in brain research2015,222:163~190.
[24] Stoker TB, Barker RA. Cell therapies for Parkinson's disease: how far have we come[J].Regenerative medicine,2016,11:777~786.
[25] Barker RA, Studer L, Cattaneo E, et al.G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease[J].NP Parkinson's Dis,2015,1:15017.
[26] Venkatesh K, Sen D. Mesenchymal stem cells as a source of dopaminergic neurons: a potential cell based therapy for parkinson's disease[J].Current stem cell research &|therapy,2016.
[27] h SM, Chang MY, Song JJ, et al. Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease[J].EMBO molecular medicine,2016,8:171.
[28] Dong J, Li S, Mo JL, et al.Nurr1-based therapies for parkinson's disease[J].CNS neuroscience &|therapeutics,2016,22:351~359.
[29] Drinkut A, Tillack K, Meka DP, et al. Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model[J].Cell death &|disease,2016,7:e2359.